Curocell readies clinical trial of revolutionary CAR-T cell therapy
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Curocell recently submitted its IND application for the clinical trial of its CAR-T cell therapy in Korea and expected to receive approval from the Ministry of Food and Drug Safety within this month, the company’s chief executive Kim Gun-soo told Maeil Business Newspaper.
Curocell already formed a strategic partnership with Samsung Medical Center to jump-start the trial upon approval, Kim said, expressing hope to deliver the innovative cancer therapy to Korean patients as early as possible.
CAR-T is a type of immunotherapy engineered to recognize and destroy cancer. To make this therapy, T cells collected from an individual patient are genetically modified within a laboratory to express cancer-specific chimeric antigen receptors. And then the modified cells are re-infused into the patient’s body to fight cancer.
CAR-T cell therapy has been proven to be more effective than any other cancer drugs developed so far. With single time treatment with a CAR-T cell infusion, 82 percent of acute leukemia patients and 32-36 percent of lymphoma patients became cancer-free after failure of other treatments, according to Kim.
The immune checkpoint receptor works like a brake on the functioning of immune cells. When the expression of immune checkpoint receptors such as PD-1 is increased, the function of immune cells to remove cancer cells decreases, making it difficult to remove tumors.
This limitation can be addressed by Curocell’s OVIS (Overcome Immune Suppression) technology, making its CAR‐T cell therapy effective in the treatment of solid tumors. OVIS is a genetic engineering technology to eliminate immune checkpoint receptor RNA (ribonucleic acid) through genetic manipulation of immune cells. In an animal model, a new CAR-T cell therapy applied with this technology was more effective than an existing CAR-T treatment, Kim said.
So far, none of the CAR-T cell therapies that are available now or in the middle of clinical trials can target both blood cancer and solid tumors, except Curocell’s treatment, according to Curocell.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Hyundai’s first all EV Ioniq 5 on E-GMP teased - Pulse by Maeil Business News Korea
- Hanwha Solutions promotes eco-friendly packaging materials for green growth - Pulse by Maeil Business News Korea
- Kia Motors, Kakao Mobility team up to stimulate EV migration in car-hailing - Pulse by Maeil Business News Korea
- Illicit stock short selling subject to tougher penalties starting April - Pulse by Maeil Business News Korea
- M&A transactions grow 15% on year in 2020 with big deals in H2 - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 총선 이후 부동산 정책 변화 짚어보니 [COVER STORY]
- “‘음악’으로 맺어진 ♥”…윤보미·라도, 8년째 열애 ‘인정’(종합)[MK★이슈] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이